Prevalence, Clinical and Virologic Outcomes of Hepatitis B Virus Co-Infection in HIV-1 Positive Kenyan Women on Antiretroviral Therapy

Summer L. Day, Katherine Odem-Davis, Kishorchandra N. Mandaliya, Keith R. Jerome, Linda Cook, Linnet N. Masese, John Scott, H. Nina Kim, Susan M. Graham, and R. Scott McClelland

Abstract

Background: Sub-Saharan Africa carries a high burden of co-infection with HIV-1 and hepatitis B virus (HBV). In this region, individuals with HIV-1/HBV co-infection on antiretroviral therapy (ART) frequently receive lamivudine as the only agent active against HBV, raising concerns for development of HBV resistance to lamivudine. We aimed to determine the prevalence, clinical, and virologic outcomes of chronic HBV infection, including HBV resistance to lamivudine, in a cohort of HIV-1 seropositive Kenyan women on long-term ART.

Methods: In this prospective cohort study, HIV-1 seropositive women initiated three-drug ART regimens that included lamivudine as the single drug active against HBV. Archived samples were tested for HBsAg, with further testing to determine HBeAg seroprevalence, HBV DNA suppression, and lamivudine resistance. We estimated the prevalence of chronic HBV and examined associations between HBV co-infection and clinical and virologic outcomes with chi-square tests, logistic regression, Kaplan-Meier and Cox regression.

Results: In a cohort of 159 women followed for a median of 3.4 years (interquartile range 1.4–4.5), 11 (6.9%; 95% CI 3.1–10.7) had chronic HBV infection. Of these, 9 (82%) achieved undetectable plasma HBV DNA levels. One woman developed lamivudine resistance, for an incidence of 3 per 100 person-years. The HBV co-infected women were at greater risk for abnormal ALT elevations compared to HIV-1 mono-infected women (HR 2.37; 95% CI 1.1–5.3). There were no differences between HBV-infected and uninfected women in mortality, CD4 count, or HIV-1 RNA suppression.

Conclusion: The prevalence of chronic HBV in this cohort was similar to recent studies from other African populations. Given our long-term follow-up, lamivudine resistance was lower than expected for HIV-1/HBV co-infected patients. Improved screening for HBV and extended follow-up of HIV-1/HBV co-infected individuals are needed to better understand the impact of different ART regimens on clinical outcomes in this population.

Introduction

In sub-Saharan Africa, 8–20% of people with HIV-1 infection are estimated to be co-infected with hepatitis B virus (HBV) [1]. In areas of high endemicity, such as sub-Saharan Africa, most individuals are infected with HBV in early childhood (due to close contact with household members) or in the perinatal period (from mother to baby at birth). In fact, it is estimated that 70–90% of individuals in the region have previously been exposed to or are chronic carriers of HBV [2]. This is in contrast to areas of low endemicity, such as in western countries, where most transmission occurs in adolescence and young adulthood due to high risk behaviors ( unprotected sexual contact and injection drug use) [3].

Compared to those with HBV infection alone, HIV-1/HBV co-infected individuals have higher HBV viral loads, decreased hepatitis B e antigen (HBeAg) seroconversion, and increased rates of liver disease [2,4,5]. Co-infection with HBV may also influence the response to antiretroviral therapy, including HIV-1 RNA suppression and increase in CD4 count [6]. The increased availability of antiretroviral therapy (ART) in resource-limited
settings has improved survival of individuals with HIV-1 [6]. As life expectancy improves, HBV can be expected to emerge as an important cause of morbidity and mortality in HIV-1 infected individuals on ART [2,7].

Beginning in 2002, World Health Organization (WHO) guidelines for first-line ART included lamivudine as the only agent active against HBV [8]. In the setting of lamivudine monotherapy, HBV resistance has been observed at rates of 20% per year in Western cohorts [9]. As of 2010, WHO guidelines recommend a first-line regimen including tenofovir and either lamivudine or entecavir in HIV-1/HBV co-infected patients [10,11]. However, in resource-limited settings HBV screening is limited, HBV status is often unknown, and tenofovir may still be unavailable [12,13]. As a result, many ART regimens in sub-Saharan Africa continue to include lamivudine as the only agent active against HBV [12–14].

Compared to studies in Western cohorts, studies of HIV-1/ HBV co-infected individuals in sub-Saharan Africa taking lamivudine-containing ART have suggested lower rates of HBV resistance to lamivudine. A cross-sectional study in Cameroon found resistance mutations in 7 (13%) of 54 patients at 24 months [12]. A retrospective analysis from The Gambia found lamivudine resistance mutations in 3 (14%) of 21 patients followed between 6 and 36 months [15]. Even lower levels of resistance were found in a recent prospective cohort study from Nairobi, Kenya, which reported that only 2 (9.5%) of 27 co-infected patients developed lamivudine resistance after 18 months of therapy [16]. Few studies in either Western or African nations have followed HIV-1/HBV co-infected patients for periods longer than 24 months. This is a concern, since the risk of resistance mutations increases with time on lamivudine [9,13], and ART is expected to be life-long. To address limitations in the available literature, we conducted a prospective cohort study over 6 years to determine the prevalence, clinical, and virologic outcomes of chronic HBV infection, including HBV resistance to lamivudine, in HIV-1 seropositive Kenyan women on long-term ART.

Methods

This prospective cohort study included HIV-1-seropositive, non-pregnant women on long-term ART. These women were part of an open cohort study established in 1993 to identify risk factors for HIV-1 acquisition in female sex workers in Mombasa, Kenya. Detailed methods for this cohort have been published previously [17,18]. Briefly, ART was offered to women eligible for treatment according to Kenyan Guidelines (CD4 cell count <200 cells/mL or AIDS-defining illness) from March 2004 through March 2010. All participants started ART containing lamivudine with nevirapine and either zidovudine or stavudine. Monthly follow-up visits included a standardized interview and physical examination according to previously published methods [17]. Blood was collected at baseline, and every three months thereafter, for monitoring of CD4 count and alanine aminotransferase (ALT) levels (Reflotron, Roche, Indianapolis, IN). Adherence was monitored at each visit by pill count (number of pills taken divided by total number expected) x100%. If patients failed to bring their medication containers to follow-up visits, adherence was calculated on the basis of patient recall.

Plasma samples were frozen at −70°C until shipment on dry ice to Seattle for HIV-1 viral load [17] and HBV assays [16]. Baseline samples were tested for hepatitis B surface antigen (HBsAg) and core antibody (HBeAg) with an ADVIA Centaur chemiluminescent immunoassay system (Siemens, Tarrytown, NY). Chronic HBV carriers were defined as HBeAg positive. All chronic HBV carriers underwent quantification of HBV DNA at baseline and quarterly thereafter. They were also tested for HBsAg and antibody using an enzyme-linked immunoassay. If HBeAg was positive, subsequent samples were tested for HBeAg seroconversion at the time of HBV DNA suppression and at the end of follow-up. HBV genotype and lamivudine resistance mutations were investigated by sequencing the YMDD region of the HBV polymerase gene at baseline and future time points if HBV DNA remained detectable (>100 copies/ml) after three months.

This analysis used the intent-to-treat principle, which included women who discontinued ART or had poor adherence. Prevalence of HBV was estimated with 95% confidence intervals (CIs) by bootstrap re-sampling. Chi-square tests were used to assess correlates of HBV infection including age, education level, alcohol use, and reported sexual risk behaviors (unprotected sex, abstinence, 100% condom use, >1 sex partners per week, >2 sex acts per week, age at first sex, and years in transactional sex). Associations of chronic HBV infection with mortality, time to CD4 lymphocyte count >350, and time to first ALT elevation were assessed by Kaplan-Meier and Cox regression. Associations with HIV-1 RNA suppression at six months and one year were examined by logistic regression. Analyses were conducted using SPSS version 18.0 (SPSS Inc., Chicago, IL) and R version 2.13 (The R Foundation, ISBN 3-900051-07-0).

Ethics Statement

Ethical review committees of the Kenya Medical Research Institute and the University of Washington approved this study. All participants provided written informed consent.

Results

This analysis included 159 HIV-1-seropositive, non-pregnant women who initiated ART and had baseline samples available for HBV testing. These women contributed 479 person-years of follow-up (median 41 months, interquartile range [IQR] 17–54 months). Twenty-seven (21%) participants were lost to follow-up (defined as greater than 60 days elapsed from previous visit at the end of the study). Seven (4.4%) women died, all of whom were HBsAg negative.

At baseline, participants' median age was 37 (IQR 33–41) years. Fifty-eight (36.5%) women reported alcohol consumption, with 7 (12%) consuming greater than 14 drinks per week. Fifteen (9.4%) women were classified as WHO clinical stage 4. The median CD4 count was 132 (IQR 80–180) cells/μL.

Eleven (7%, 95% CI 3–11) of 159 women were chronic HBV carriers, and these women were followed for a median of 33 (IQR 22–44) months, contributing to a total of 33 person-years of follow-up. An additional 84 (53%, 95% CI 45–61) women had a prior history of HBV infection (HBsAg negative and HBeAb positive). Chronic carriers (HBsAg positive) were more likely to report consuming >14 alcoholic drinks per week (OR 7.68, 95% CI 1.18–49.8) and less likely to report >1 year of transactional sex work at enrollment (OR 0.23, 95% CI 0.06–0.82). Chronic HBV carriers did not differ significantly from other women with respect to age, education level, or reported sexual risk behaviors.

Ten of eleven chronic HBV carriers were infected with HBV genotype A1 (Table 1). One woman (participant 1) did not have baseline HBV DNA levels sufficient for genotypic testing. No baseline lamivudine resistance mutations were detected. Six (55%) of 11 chronic HBV carriers were HBeAg positive at baseline. One participant achieved HBeAg seroconversion after 87 days of ART. Undetectable HBV DNA levels were attained in 9 (82%) women after a median of 88 (IQR 70–322) days. Only one woman...
### Table 1. Clinical characteristics and treatment outcomes in HIV-1/HBV co-infected Kenyan women.

| Participant | Hepatitis B Genotype | HBeAg | HBV DNA Level (IU/mL) | Days to HBV DNA Suppression<sup>a</sup> | Resistance Mutation | Total follow-up time (months) | Maximum ALT<sup>b</sup> (U/L) | Mean Adherence (percent)<sup>c</sup> |
|-------------|----------------------|-------|-----------------------|----------------------------------------|--------------------|-------------------------------|-------------------|-----------------------------|
| 1           | Quantity n/s<sup>d</sup> | Negative | 350                  | 88                                    | Below limit<sup>e</sup> | 33                           | 36                | 100                         |
| 2           | A1                   | Negative | 1,700               | 86                                    | Below limit        | 37                           | 34                | 92                          |
| 3           | A1                   | Negative | 5,400               | 28                                    | Below limit        | 71                           | 20                | 98                          |
| 4           | A1                   | Negative | 32,000              | 85                                    | Below limit        | 38                           | 11                | 98                          |
| 5           | A1                   | Negative | 63,000              | 28                                    | Below limit        | 10                           | 11                | 100                         |
| 6           | A1                   | Positive<sup>f</sup> | 2,700,000          | 87                                    | Below limit        | 11                           | 54                | 98                          |
| 7<sup>g</sup> | A1                   | Positive | 4,600,000          | 392                                    | None               | 30                           | 136               | 79                          |
| 8           | A1                   | Positive | 290,000,000       | 262                                    | None               | 51                           | 14                | 97                          |
| 9           | A1                   | Positive | 300,000,000       | 298                                    | None<sup>h</sup>               | 17                           | 51                | 95                          |
| 10<sup>i</sup> | A1                   | Positive | 490,000,000      | Never suppressed                      | M204I              | 73                           | 20                | 97                          |
| 11<sup>j</sup> | A1                   | Positive | 1,800,000,000 | Never suppressed                      | None               | 27                           | 14                | 88                          |

HBeAg, hepatitis B e antigen. HBV, hepatitis B virus.

<sup>a</sup>HBV DNA Suppression defined as ≤100 IU/mL.

<sup>b</sup>Upper limit of normal for ALT assay is 17 U/L.

<sup>c</sup>Mean adherence calculated from pill count across all visits. If pill count unavailable, used patient recall of pills taken.

<sup>d</sup>Quantity n/s, quantity not sufficient for baseline genotype analysis.

<sup>e</sup>If HBV DNA < 100 IU/mL after 3 months, samples were below the limit for detection and sequencing was not performed.

<sup>f</sup>This woman seroconverted for HBeAg at day 87 of ART.

<sup>g</sup>This woman developed ALT elevations and had to discontinue ART at day 58; she resumed at day 334 and initially suppressed HBV DNA at day 392; she was noted to have poor adherence and HBV DNA relapse at day 456.

<sup>h</sup>Had baseline mutation V173L.

<sup>i</sup>This woman developed the M204I lamivudine resistance mutation at day 392 of ART; the lowest HBV DNA level achieved was 1100 IU/mL at day 1320 of ART.

<sup>j</sup>This woman was noted to have poor adherence (88%); the lowest HBV DNA level achieved was 44,000 IU/mL at day 351 of ART.

doi:10.1371/journal.pone.0059346.t001
HBV genotype A1 was identified. While our cohort in Mombasa [16]. Interestingly, in both our study and the Nairobi study, only lamivudine resistance to the present study (7/100 person-years) adults in Nairobi, Kenya found a similarly low incidence of questions persist as to whether HBV genotypes influence response mutations in genotype B compared to C [32,33]. In summary, the scale prospective studies from China show higher rates of YMDD patients from different ethnicities [30,31]. However, recent large-
failed to demonstrate a clear role of genotype in determining tion showed that this difference did not persist beyond one year of A and D, respectively [24]. However, prolonged clinical observa-
tions account for differences in clinical outcomes including development of lamivudine resistance mutations [22].

HBV has been classified into 8 genotypes, A-H, with genotypes A, D, and E predominant in sub-Saharan Africa [22,23]. An early study of patients in Germany suggested a 20-fold increased risk of lamivudine resistance in a small cohort (n = 26) with HBV serotype adw compared to ayw (corresponding to genotypes A and D, respectively [24]. However, prolonged clinical observation showed that this difference did not persist beyond one year of therapy [25,26]. Several subsequent studies comparing genotypes from Asia [27–29], Australia [30], and North America [31] have failed to demonstrate a clear role of genotype in determining clinical outcomes. Problems with these studies include small sample size [28], cross-sectional design [31], and pooling of patients from different ethnicities [30,31]. However, recent large-scale prospective studies from China show higher rates of YMDD mutations in genotype B compared to C [32,33]. In summary, the available literature provides a somewhat conflicting picture, and questions persist as to whether HBV genotypes influence response to therapy and lamivudine resistance.

A recent prospective cohort study of HIV-1/HBV co-infected adults in Nairobi, Kenya found a similarly low incidence of lamivudine resistance to the present study (7/100 person-years) [16]. Interestingly, in both our study and the Nairobi study, only HBV genotype A1 was identified. While our cohort in Mombasa had a lower absolute number of chronic HBV carriers (11/159 [6.9%] versus 27/389 [6.9%]), the participants contributed substantially longer periods of follow-up (median 33 versus 16 months). The present cohort also differed from the Nairobi cohort by having higher baseline HBV DNA levels (73% versus 33% with HBV DNA >10,000 IU/mL and HBeAg-positivity (55% versus 11%), both of which have been associated with increased risk of lamivudine resistance [20,34,35]. With such different markers of HBV infection but similarly low rates of lamivudine resistance, these studies suggest that HBV treatment outcomes to lamivudine monotherapy in the region may be distinct from what has been published elsewhere.

The unique strength of our study was the extended period of follow-up of this prospective cohort, which enabled us to ascertain virologic outcomes over a substantially longer period than previous studies [9,12,16,34]. In addition, we included all individuals with HIV-1/ HBV co-infection on ART in an intent-to-treat analysis. In contrast, some studies in both Western and African cohorts have included only the subset of participants who have detectable plasma HBV DNA during follow-up [12,20]. This approach may overestimate lamivudine resistance by excluding participants with sustained undetectable plasma HBV DNA levels.

The main limitation of this study was the relatively small number of women with chronic HBV infection. Although loss to follow-up in this study would not affect baseline prevalence estimates of HIV-1/ HBV co-infection, it could limit evaluation of outcomes. In addition, this exploratory study included multiple statistical comparisons, affecting our ability to interpret significant results. Since time on lamivudine is a risk factor for development of lamivudine resistance [9], using the intent-to-treat principle and leaving HIV-1/ HBV co-infected individuals who discontinue lamivudine in the analysis could falsely lower our detection of resistance mutations. However, only one of 11 women (participant 7) discontinued lamivudine but remained in follow-up. This study did not include testing for hepatitis C or hepatitis D, both of which are important co-infections in HIV-infected individuals. However, their exclusion should not limit interpretation of the HBV results. Finally, the ADVIA Centaur HBsAg assay used in this study may be limited in its ability to detect certain HBsAg mutants [36,37]. The significance of this limitation is difficult to assess, as prevalence estimates of HBsAg mutants in sub-Saharan Africa are not widely available. A recent study evaluating 11,221 HBV sequences of genotypes A-H demonstrated a low prevalence of HBsAg variants in genotype A viruses (54/1,524, or 3.6%) [38]. Failure to detect HBsAg mutants in our present study could have resulted in a small number of missed cases of chronic HBV infection.

As increased access to ART increases life expectancy of HIV-1/ HBV co-infected individuals in sub-Saharan Africa, HBV is expected to be an important cause of morbidity and mortality in these individuals [2,6,7]. As of 2010, WHO recommends HBV screening before initiating ART, and using ART regimens containing tenofovir with either lamivudine or emtricitabine for HIV-1/ HBV co-infection [10,11]. However, in resource limited settings, HBV screening may be unavailable [13]. As a result, many HIV-1/ HBV co-infected adults are likely to be exposed to lamivudine monotherapy as part of first or second-line ART regimens. Our study was conducted in a high risk population of women in East Africa, and these results may not be generalizable to men or other regions where different genotypes are encountered. Nonetheless, our results suggest that the incidence of HBV genotypic resistance during lamivudine monotherapy may be lower in some populations. This was also suggested in a recent Canadian study of 47 HBV mono-infected adults on lamivudine
for a mean of 32 months. Sustained HBV DNA suppression was observed in 89% of patients, and they concluded that lamivudine monotherapy may be appropriate in some populations [39]. It will be important to study larger cohorts from diverse regions to determine the impact of different ART regimens on the clinical outcomes of HIV/HBV co-infection. Expanding use of HBV screening could facilitate rational sequencing of antiretrovirals for these patients, potentially leading to improved long term outcomes.

Acknowledgments

We thank our clinical laboratory, outreach, and administrative staff for their important contributions to the success of this work. We also wish to express our appreciation to the Mombasa Municipal Council for providing clinical space and Coast Provincial General Hospital for providing laboratory space. Special thanks go to our study participants, without whose time and effort this study would not have been possible.

Author Contributions

Revised the manuscript and had final approval: RSM SMG KJF HNB LNM KNM KOD SLD. Conceived and designed the experiments: RSM SMG KJF HNB LNM KOD SLD. Performed the experiments: KJF LC LNM KNM. Analyzed the data: SLD KOD. Contributed reagents/materials/analysis tools: LNM KNM KJF LC. Wrote the paper: SLD.

References

1. Modi AA, Feld JJ (2007) Viral hepatitis and HIV in Africa. AIDS Rev 9: 25–39.
2. Hoffmann CJ, Thio CL (2007) Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 7: 402–409.
3. Lewansky D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97–107.
4. Soriaño V, Puoti M, Peters M, Benhamou X, Sulkowski M, et al. (2008) Care of HIV patients with chronic hepatitis B: updated recommendations from the European Association for the Study of the Liver. J Viral Hepat International Panel. AIDS 22: 1399–1410.
5. Puoti M, Torri C, Bruno R, Ficile G, Carosi G (2006) Natural history of chronic hepatitis B in co-infected patients. J Hepatol 44: 865–870.
6. Hoffmann CJ, Charalabous S, Desmond MJ, Tunnes C, Churchyard GJ, et al. (2008) Hepatitis B virus infection and response to Antiretroviral Therapy (ART) in a South African ART Program. Clin Infect Dis 47: 1479–1485.
7. Barth RE, Huigen Q, Taljaard J, Hoepelman AI (2010) Hepatitis B/C and HIV coinfection in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 14: e1024–e1031.
8. Ford N, Calmy A (2010) Improving first-line antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS 5: 38–47.
9. Benhamou X, Bocher M, Thibault V, Martino VD, Caumes E, et al. (1999) Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30: 1302–1306.
10. UNAIDS (2010) Global Report: UNAIDS report on the global HIV epidemic. Geneva: Available: http://www.unaids.org/globalreport/global_report.htm. Accessed 2012 Sep 10. 1–364.
11. World Health Organization (WHO) (2010 Revision) Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. Available: http://www.who.int/hiv/pubguidelines/adulten/index.html. Accessed 2012 May 10.
12. Konanfack C, Agbodjegn AF, Mondiali AM, Bourgeois A, Kenfack A, et al. (2009) Harmful and helpful outcomes in HIV infected patients receiving antiretroviral therapy in a public routine clinic in Cameroon. Antivir Ther 14: 321–326.
13. Matthews GV, Manzini P, Hu Z, Khabo P, Maja P, et al. (2011) Impact of lamivudine on HIV-1 and hepatitis B virus-related outcomes in hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS 25: 1727–1735.
14. Geretti AM, Patel M, Sarfo FS, Chadwick D, Verheyen J, et al. (2010) Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana. J Clin Microbiol 48: 3223–3229.
15. Stewart B, Joharite J, Sarge-Njie R, Alahi A, Peterson K, et al. (2011) Emergence of HIV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa. BMC Res Notes 4: 561.
16. Kim NH, Scott J, Cent A, Cook L, Morrow RA, et al. (2011) HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine, and tenofovir in Kenya. J Viral Hepat 18: e447–452.
17. Graham SM, Masae L, Gitau R, Jalaluddin L, Richardson BA, et al. (2010) Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment. J Infect Dis 202: 1538–1542.
18. McGlade RS, Hassan W, Lavery L, Richardson BA, Mandaliya K, et al. (2006) HIV-1 acquisition and disease progression are associated with decreased high-risk sexual behaviour among Kenyan female sex workers. AIDS 20: 1969–1973.
19. Law V, Gore G, Duncombe C, Mahanonharit A, Boyd MA, et al. (2003) Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996–2001. AIDS 17: 2191–2199.
20. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sadasivan J, et al. (2006) Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 20: 863–870.
21. Ramos B, Nunez M, Martin-Carbonero L, Sheldon J, Rieu P, et al. (2007) Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/ hepatitis B virus-infected patients. J Acquir Immune Defic Syndr 44: 537–561.
22. Kramvis A, Kew M (2005) Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat 12: 456–464.
23. Liu C, Kao J, Chen D (2005) Therapeutic Implications of hepatitis B virus genotypes. Liver International 25: 1097–1107.
24. Zolliker F, Schafer P, Frricht H, Scherotz M, Petersen J, et al. (2001) Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy. J Med Virol 65: 659–663.
25. Liu C, Kao J, Chen D (2002) Hepatitis B virus genotypes and lamivudine resistance. J Hepatol 36: 303–304.
26. Akuta N, Suzuki F, Kabayashi M, Tsurolla A, Suzuki Y, et al. (2003) The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J Hepatol 38: 321–326.
27. Kosowicz D, Obasuyi C, Ghebremedhin E, Healthcote E (2005) Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J Viral Hepat 12: 398–404.
28. Liu X, Wang L, Liu Y, Xu Z, Dai J, et al. (2011) Characterization of hepatitis B virus genotypes/subgenotypes in 1,301 patients with chronic hepatitis B in North China. Chin Med J 124: 4176–4183.
29. Wu F, Wu M, Zhuge X, Zhu S, Zhu B (2012) Correlation of the occurrence of YMDD mutations with HBV genotypes, HBV-DNA levels, and HBcAg status in Chinese patients with chronic hepatitis B during lamivudine treatment. Hepatobiliary Pancreat Dis Int 11: 172–176.
30. Lai CL, Dienstag J, Schiff E, Leung NW, Akmins M, et al. (2003) Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36: 607–696.
31. Wongsirat P, Manousuthi W, Kiertiburanakul S, Sunghansuphar S (2010) Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy. AIDS Pat Care STDs 24: 205–209.
32. Moerman B, Moons V, Sommer H, Schmitt Y, Nester M (2004) Evaluation of sensitivity for wild type and mutant forms of hepatitis B surface antigen by four commercial HBcAg assays. Clin Lab 50: 159–169.
33. Lu’ulu S, Roberts W (2006) The analytic sensitivity and mutant detection capability of six hepatitis B surface antigen assays. Am J Clin Pathol 122: 748–751.
34. Ma Q, Wang Y (2012) Comprehensive analysis of the prevalence of hepatitis B virus escape mutations in the major hydrophilic region of surface antigen. J Med Virol 84: 198–206.
35. Shahid T, Cooper G (2012) Reassessing the role of lamivudine in chronic hepatitis B infection: a four-year cohort analysis. Can J Gastroenterol 26: 144–150.